GlaxoSmithKline has dropped plans to sell part of its HIV drugs unit and promised to hold its dividend steady for the next three years as the struggling UK pharmaceuticals group set out its strategy to revive growth.
葛蘭素史克(GlaxoSmithKline，簡稱GSK)已放棄了轉讓部分愛滋病(HIV)藥物部門的計劃，並承諾要在今後三年內保證其穩定分紅。這家深陷困境的英國製藥集團正要著手實施其重獲成長的戰略。
您已閱讀7%（314字），剩餘93%（4516字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。